Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Common Equity (2020 - 2025)

Historic Common Equity for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to $1.2 million.

  • Ensysce Biosciences' Common Equity fell 8258.07% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 8258.07%. This contributed to the annual value of $3.7 million for FY2024, which is 66941.65% up from last year.
  • According to the latest figures from Q3 2025, Ensysce Biosciences' Common Equity is $1.2 million, which was down 8258.07% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Common Equity ranged from a high of $6.9 million in Q3 2024 and a low of -$8.2 million during Q4 2021
  • For the 5-year period, Ensysce Biosciences' Common Equity averaged around $504740.4, with its median value being $1.3 million (2022).
  • As far as peak fluctuations go, Ensysce Biosciences' Common Equity plummeted by 156679.18% in 2022, and later surged by 66941.65% in 2024.
  • Ensysce Biosciences' Common Equity (Quarter) stood at -$8.2 million in 2021, then surged by 50.61% to -$4.0 million in 2022, then soared by 83.84% to -$651267.0 in 2023, then surged by 669.42% to $3.7 million in 2024, then tumbled by 67.55% to $1.2 million in 2025.
  • Its Common Equity was $1.2 million in Q3 2025, compared to $3.4 million in Q2 2025 and $3.0 million in Q1 2025.